Chromosome alterations commonly found in cancer cells include gene fusions, gross chromosomal rearrangements, and copy number variants. The chromosomal aberrations involved in cancer are often assessed through cytogenetic analysis, which is an integral part of current genomic clinical research.
Cytogeneticists can now use complementary microarray and next-generation sequencing (NGS) technologies for thorough analysis of chromosomal changes in cancer to obtain a comprehensive view of genomic alterations, both large and small.
Many scientists now use microarrays as a screening tool for increasing their understanding of cancer cytogenetics. Traditional methods for assessing chromosomal abnormalities, including fluorescence in situ hybridization (FISH) and karyotyping, generally provide low resolution, resulting in more limited data.1 Arrays offer a simple, reliable method for identifying copy number changes and unbalanced translocations with high resolution and high throughput.Learn More
By providing a base-by-base view of the entire genome, NGS can identify point mutations, small indels, and gene fusion breakpoints. This information can help to identify molecular subtypes, prognostic biomarkers, and other indicators that can inform therapeutic strategies.Learn More
Labs are inundated with samples, so gaining efficiency is critical. NGS can complement FISH, saving you time and money, while enabling you to meet best practices for analyzing samples with unknown abnormalities.View Infographic
By combining NGS and microarrays, clinical researchers can obtain a comprehensive view of cancer cytogenetics.
Illumina products facilitate clinical cancer research by providing expert-defined gene content2,3,4, accurate data, and simple analysis and reporting options.
Click on the below to view products for each workflow step.
Designed by international consortia to provide the most comprehensive coverage of cytogenetically relevant genes for cancer studies.
Perform sequencing and high-quality cytogenomic array scanning, all on a single system.
A gene fusion detection panel targeting fusion associated genes in many cancer types with the ability to detect known and novel fusion gene partners.TruSight Tumor 15
Focused panel to assess relevant solid tumor somatic variants in a simple, sample-to-data workflow.TruSight Myeloid Sequencing Panel
Expert-defined panel* targeting oncogenic exons and tumor suppressor genes for myeloid malignancies.TruSight Cancer Sequencing Panel
A panel designed in collaboration with the Institute of Cancer Research that targets 94 genes and 284 SNPs associated with a predisposition towards cancer.
* List of experts on file.
Intuitive software that provides molecular cytogenetic and Preimplantation Genetic Screening (PGS) data analysis in a single framework.Local Run Manager
Easy-to-use software for automated on-instrument data analysis.